Please login to the form below

Not currently logged in

Silence Therapeutics

This page shows the latest Silence Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Optimum wins Silence Therapeutics account

Optimum wins Silence Therapeutics account

The healthcare communications group will advise in financial PR. London, UK-based Optimum Strategic Communications has been appointed by RNAi-focused Silence Therapeutics. ... Working with US strategic partner Burns McClellan, the healthcare

Latest news

  • mRNA - message received mRNA - message received

    mRNA replacement opens up entirely new therapeutic areas,” according to Ali Mortazavi, chief executive of UK firm Silence Therapeutics that has just raised almost £40m ($62m) in a fundraising round. ... Silence Therapeutics. undisclosed. Antigen

  • Sanofi strikes $700m rare diseases deal Sanofi strikes $700m rare diseases deal

    This pipeline features a series of RNAi therapeutics designed to 'silence' mutated genes in rare genetic diseases in order to stop the disease-causing proteins from being formed.

  • Oncology bias in pharma deals

    Silence Therapeutics and miRNA Therapeutics have also signed a collaboration to evaluate delivery of novel microRNA Therapeutics, via Silence's AtuPLEX and DBTC delivery systems. ... not known. Silence Therapeutics/ miRNA Therapeutics. R&D collaboration.

  • Dr Georg Buchner joins Silence Therapeutics

    He assumes a business development role at the London-based biotech. London-based biotech Silence Therapeutics has appointed Dr Georg Buchner VP, business development. ... Silence's CEO Thomas Christély said: "We are pleased to welcome Dr Georg Buchner

  • AZ and Silence extend collaboration

    A one-year continuation to a project between AstraZeneca and Silence Therapeutics developing five siRNA programmes has been announced. ... We are very pleased with the progress we have made in our collaborative agreement with Silence Therapeutics.".

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest appointments

  • Pharma industry appointments Pharma industry appointments

    Silence Therapeutics strengthens board and leadership team. Dave Lemus (pictured) has joined Silence Therapeutics’ board as a non-executive director. ... At Silence Therapeutics, Jenkins will be heading the clinical development function, reporting

  • Silence Therapeutics appoints Dr Annalisa Jenkins as non-executive chair Silence Therapeutics appoints Dr Annalisa Jenkins as non-executive chair

    RNA-focused group Silence Therapeutics has appointed Dimension Therapeutics chief executive officer Dr Annalisa Jenkins as the non-executive chair of its board of directors. ... forchief executive officer, Silence Therapeutics, said: “Annalisa’s

  • Silence Therapeutics' Ali Mortazavi appointed chairman of ultromics Silence Therapeutics' Ali Mortazavi appointed chairman of ultromics

    Silence Therapeutics' chief executive officer Ali Mortazavi has been appointed non-executive chairman of ultromics - an artificial intelligence-focused medical imaging firm. ... Mortazavi has 17 years’ experience in UK companies, particularly in the

  • Silence Therapeutics adds to leadership team Silence Therapeutics adds to leadership team

    I look forward to working closely with him.”. Meanwhile, Silence Therapeutics has also appointed Dr Andy Richards as non-executive director and a member of the board with immediate effect. ... Dr Stephen Parker, chairman of Silence Therapeutics, said:

  • Stuart Collinson joins Silence Therapeutics Stuart Collinson joins Silence Therapeutics

    He replaces Simon Sturge as non-executive director. Silence Therapeutics has appointed Dr Stuart Collinson as its new non-executive director and chair of its remuneration committee with immediate effect. ... Essentialis. Chief executive officer of

More from appointments
Approximately 7 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...